Podcasts about Research institute

The news of Texas covered today includes:Our Lone Star story of the day: Respected judge on the Fifth Circuit Court of Appeals, Jerry Smith, says of the ruling blocking Texas Congressional redistricting: “If this were a law school exam, the opinion would deserve an F.” Smith called the action of district court judges Brown and Guaderrama “outrageous conduct.” Smith said of the three judge panel that it was the worst he has ever seen in a case in which he was involved and accused Brown of “pernicious judicial misbehavior.”It wasn't just the terrible legal opinion, Brown and Guaderrama appear to have short circuited the judicial process with an attempt to derail Judge Smith's dissenting opinion. Judge's scathing dissent casts redistricting ruling as ‘judicial activism' Dissenting Judge Slams Colleagues for Blocking Texas Congressional Map ‘Nobel Prize for Fiction': Federal Judge Issues Fiery Dissent to Texas Congressional Redistricting Ruling Judge in Texas redistricting case slams move to strike down new map In addition, this is a must read: SCOTUS must save Texas from meddling liberal judges, by Mike Davis.Our Lone Star story of the day is sponsored by Allied Compliance Services providing the best service in DOT, business and personal drug and alcohol testing since 1995.Lt. Gov. Patrick spitting nails over a lawsuit filed over the creation of his favored new bureaucracy, the Dementia Prevention and Research Institute of Texas.Attorney General Ken Paxton gets a win for law and order over Harris County's Soros-style soft on bail policies.TX19: Republican Abraham Enriquez announces campaign for Congress in Texas' 19th District.Listen on the radio, or station stream, at 5pm Central. Click for our radio and streaming affiliates.www.PrattonTexas.com

The African National Congress' (ANC's) idea of transformation is transforming tax money into Maseratis for cadres. “It's not transforming anything else”. So says Connie Mulder, the Head of Solidarity's Research Institute, in this interview with Chris Steyn. “When you're talking about treasonous behaviour and unpatriotic behavior, I would much rather argue using the State coffers as your own personal piggy bank for more than a decade, as the ANC has done, is much more treasonous than trying desperately to salvage the relationship with our second biggest trade partner, which Solidarity has tried to do.” Mulder points out that even China has started applying pressure on the ANC's BEE policy “saying, you're deterring investment, you're making it difficult for us to come in and invest”. He outlines how Solidarity is using the upcoming G20 summit in South Africa to intensify lobbying. Giving an update on the saga of the removal of its banner that proclaims “Welcome to the most race regulated country in the world”, he confirms the City of Joburg has returned it at no cost. “And we put up 38 more billboards.” He also gives feedback on the ANC's response to the documentary “Race to the Bottom”.

Today, we're thinking about Marcyliena Morgan, a keeper extraordinaire, a linguistic anthropologist who founded and championed the Hip Hop Archive at Harvard. Marcyliena Hazel Morgan was born in Chicago, May 8, 1950 and passed away September 28, 2025. We were fortunate to interview her in 2018 as part of the opening story in our NPR series The Keepers, about activist archivists, rogue librarians, curators, collectors and historians. Keepers of the culture and the cultures and collections they keep. Guardians of history large and small, protectors of the free flow of information and ideas. Individuals who take it upon themselves to preserve some part of our cultural heritage. Marcyliena Morgan was all that and more. Our story delves into the the founding of the Hip Hop Archive and Research Institute at Harvard by Dr. Morgan and Professor Henry Louis Gates Jr. to “facilitate and encourage the pursuit of knowledge, art, culture, scholarship and responsible leadership through Hiphop.”You'll hear from Professor Morgan, Professor Gates, Nas, Patrick Douthit aka 9th Wonder, an array of Harvard archivists and students studying at the archive as well as the records, music and voices being preserved there. We've also included more of our original interview with Dr. Morgan. The Kitchen Sisters Present is produced by The Kitchen Sisters (Davia Nelson & Nikki Silva) with Nathan Dalton and Brandi Howell. We're part of the Radiotopia Network from PRX. 

Featuring perspectives from Dr Matthew Lunning and Dr Sonali M Smith, including the following topics:  Which Driver and Which Race: CAR-T and Bispecific Antibodies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Lunning (0:00) Available and Emerging Novel Therapies for Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Smith (32:37) CE information and select publications

Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here.

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics:  Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer — Dr Lieu (0:00) Other Biomarker-Based Strategies for Patients with Colorectal Cancer — Dr Strickler (36:39) CE information and select publications

In this episode with Dr Tim Mcgrath we explore return to play assessment of athletes post ACL reconstruction. We discuss:The importance of making the rehab specific to the patient's end goalHigh risk manoeuvres in rehab/return to play (RTP)How important is RTP testing?RTP testing essentials This episode is closely tied to Tim's Practical he did with us. With Practicals you can see exactly how top experts assess and treat specific conditions – so you can become a better clinician, faster.

Dr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. CME information and select publications here.

Dr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. CME information and select publications here.

Dr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. CME information and select publications here.

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics:  Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Smith (0:55) Available and Emerging Therapeutic Approaches for Metastatic Castration-Resistant Prostate Cancer — Dr Antonarakis (26:37) CE information and select publications

Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. CME information and select publications here.

Featuring perspectives from Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda, including the following topics:  Introduction (0:00) Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease — Dr Goetz (4:48) Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Nanda (29:45) Management of HER2-Positive Breast Cancer — Dr Burstein (1:04:43) Antibody-Drug Conjugate Treatment Approaches for Triple-Negative Breast Cancer — Dr McArthur (1:29:53) CE information and select publications

Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. CME information and select publications here.

1 in 4 immigration arrests are happening in Texas under the Trump administration. We’ll take a look at the statewide crackdown.It’s Election Day. One constitutional amendment that funds a new Dementia Prevention and Research Institute for the state’s aging population is on the ballot.A look back at our top 10 author interviews as the Standard […] The post Data reveals intensity of ICE crackdown in Texas under Trump appeared first on KUT & KUTX Studios -- Podcasts.

Parkinson's cases are rising. Dr. Ray Dorsey says our environment is a big reason why. In “The Parkinson's Plan,” Dorsey and co-author Dr. Michael Okun argue that modifiable environmental exposures are fueling the disease, and they outline practical steps to reduce risk and improve treatment.Dorsey is a professor of neurology at the University of Rochester and a public health advocate focused on eliminating toxic exposures linked to neurodegenerative disease. A co-author of “Ending Parkinson's Disease,” he has testified before Congress, advised the World Health Organization and was recognized by the White House as a Champion for Change. He also serves as the founding director of the Center for the Brain & Environment at Atria Health and Research Institute.In this conversation with Being Patient founder Deborah Kan, Dorsey explains why most Parkinson's cases appear to be driven more by environmental chemicals than by genes, and what that means for prevention. He outlines practical steps — from reducing pesticide and solvent exposure to filtering water and air — alongside evidence-backed habits like vigorous exercise and getting specialist care. —-If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/

Luke Grant chats with Allergy epidemiologist Associate Professor Rachel Peters from the Murdoch Children’s Research Institute about new research from the United States shows a solid decline in childhood food allergies following changes in infant feeding advice.See omnystudio.com/listener for privacy information.

We've all been there—juggling new tech, new expectations, and wondering if our students are really learning what matters. In this chat, we talk about “pedagogical debt” (the gap between what we know works in teaching and what we actually do), how AI is shaking things up, and why the right kind of curiosity can help. At its heart, it's a conversation about making sure technology serves learning—not the other way around. Dr. Punya Mishra (punyamishra.com) is the Associate Dean of Scholarship and Innovation at the Mary Lou Fulton Teachers College at Arizona State University. He has an undergraduate degree in Electrical Engineering, two Master's degrees in Visual Communication and Mass Communications, and a Ph.D. in Educational psychology. He co-developed the TPACK framework, described as “the most significant advancement in technology integration in the past 25 years.” Dr. Caroline Fell Kurban is the advisor to the Rector at MEF University. She was the founding Director of the Center of Research and Best Practices for Learning and Teaching (CELT) at MEF University and teaches in the Faculty of Education. She holds a BSc in Geology, an MSc in TESOL, an MA in Technology and Learning Design, and a PhD in Applied Linguistics. Fell Kurban is currently the head of the Global Terminology Project and the creator of the GenAI-U technology integration framework. Dr. Liz Kolb is a clinical professor at the University of Michigan and the author of several books, including Cell Phones in the Classroom and Help Your Child Learn with Cell Phones and Web 2.0. Kolb has been a featured and keynote speaker at conferences throughout the U.S. and Canada. She created the Triple E Framework for effective teaching with digital technologies and blogs at cellphonesinlearning.com. Dr. Puentedura is the Founder and President of Hippasus, a consulting practice focusing on transformative applications of information technologies to education. He has implemented these approaches for over thirty years at various K-20 institutions and health and arts organizations. He is the creator of the SAMR model for selecting, using, and evaluating technology in education and has guided multiple projects worldwide. Dr. Helen Crompton is the Executive Director of the Research Institute for Digital Innovation in Learning at ODUGlobal and Professor of Instructional Technology at Old Dominion University. Dr. Crompton earned her Ph.D. in educational technology and mathematics education from the University of North Carolina at Chapel ill. Dr. Crompton is recognized for her outstanding contributions and is on Stanford's esteemed list of the world's Top 2% of Scientists. She is the creator of the SETI framework. She frequently serves as a consultant for various governments and bilateral and multilateral organizations, such as the United Nations and the World Bank, on driving meaningful change in educational technology.

Dr. Mark Krstic is the Managing Director of the Australian Wine Research Institute (AWRI). With more than 28 years of experience in grape and wine research and development, he is also a Professor at Macquarie University, a published author, and a respected leader across numerous boards, committees, and industry programs. His breadth of expertise positions him as one of the most influential figures in the advancement of Australian wine. https://www.awri.com.au SUBSCRIBE TO OUR NEWSLETTER FOR EXCLUSIVE ARTICLES, NEWS, GIVEAWAYS AND BEHIND THE SCENES https://deepintheweeds.us6.list-manage.com/subscribe?u=d33e307cf7100cf947e2e6973&id=d17d8213f5 Follow Over a Glass https://www.instagram.com/overtheglasspod  Host Shanteh Wale https://www.instagram.com/shantehwale/?hl=en Executive Producer Rob Locke https://www.instagram.com/foodwinedine/ Executive Producer Anthony Huckstep https://www.instagram.com/huckstergram/ LISTEN TO OUR OTHER FOOD PODCASTS https://linktr.ee/DeepintheWeedsNetwork Over a Glass is a wine & drinks podcast with Shanteh Wale exploring the personalities, stories and landscape of the wine and drinks business. An Australian Wine and Drinks Podcast from the Deep in the Weeds Network.

This podcast is powered by LSJS. Visit lsjs.ac.uk to learn about our Jewish learning journeys & find something that suits you. NEW! Talk to us at womensgallery@lsjs.ac.uk and tell us about amazing women who you'd like to hear interviewed. Joanne Greenaway is joined by Rabbanit Chana Henkin, founder of Nishmat: The Jeanie Schottenstein Center for Advanced Torah Study for Women in Jerusalem, and Head of its Research Institute. One of the great pioneers of women's Orthodox Torah scholarship, Rabbanit Henkin has transformed the landscape of women's halachic and spiritual leadership. Together with her late husband, Rav Yehuda Henkin ztz"l, she founded the Yoatzot Halacha programme, training women experts in Jewish law and women's health, whose work has changed the way halachic guidance is sought and given across the Orthodox world. A beloved teacher and visionary, Rabbanit Henkin has received honorary doctorates from both Bar-Ilan and Yeshiva Universities and was awarded Israel's prestigious Agrest Prize for innovative religious education. She reflects on resilience amid personal loss, explains the vacuum that prompted her to start the Yoatzot Halacha programme, discusses continuing her late husband's work on women in halacha and demonstrates how halacha has given agency to women. We discuss the difference between a yoetzet and a rabbi, and the changing relationships between women and rabbis in the information age, and she inspires us with a message about serving the community in the future. Responsa on Contemporary Jewish Women's Issues (New Expanded Edition) is available here. To access our full LSJS programme of learning, visit lsjs.ac.uk/learning. Our new women's gemara course, A Taste of Talmud starts on Wed 22nd October. Book it for free here.  

The fastest-growing brain disease in the world is almost entirely preventable. So why are cases of Parkinson's Disease skyrocketing?  In THE PARKINSON'S PLAN, leading neurologists Dr. Ray Dorsey and Dr. Michael Okun explore how chemicals — including those banned in dozens of countries but still used widely the in U.S. — are fueling a hidden Parkinson's epidemic.  Dr. Ray Dorsey is Director of The Center for the Brain and Environment at Atria Health and Research Institute in NYC, and Dr. Michael Okun is Director of the Norman Fixel Institute for Neurological Diseases at The University of Florida Health.

Here's a preview of a new show from our friends at Pushkin Industries and the Atira Health and Research Institute. On Decoding Women's Health, Dr. Elizabeth Poynor makes the science of women's health accessible—from hormones to metabolism to longevity—so you can thrive at any stage of life. A world-renowned gynecologic oncologist and advanced pelvic surgeon, Dr. Poynor speaks with leading physicians, researchers, and educators to share the latest science on women's wellness, disease prevention, and what it really means to age on your own terms. Each episode explores a different aspect of how to improve your health during midlife—from heart disease and genetic risks to cognitive health and beyond. Because mid-life isn't a crisis—it's an opportunity. Find Decoding Women's Health with Dr. Elizabeth Poynor wherever you get podcasts. Check out our offerings & partners: Beam Dream Powder: Visit https://shopbeam.com/GOODLIFE and use code GOODLIFE to get our exclusive discount of up to 40% off. Hosted on Acast. See acast.com/privacy for more information.

Welcome to the award-winning The Hill Country Podcast. The Texas Hill Country is one of the most beautiful places on earth. In this podcast, Hill Country resident Tom Fox visits with the people and organizations that make this the most unique area of Texas. This week, Tom welcomes Melissa Sanchez, the Senior Director of Public Policy at the Alzheimer's Association, to discuss her role and key initiatives, including Proposition 14. Melissa shares insights into her professional journey, emphasizing the importance of public policy in shaping lived experiences. The discussion delves into Proposition 14, a significant initiative aiming to transfer $3 billion over ten years to support the Dementia Prevention and Research Institute of Texas, mirroring the success of the Cancer Prevention and Research Institute of Texas. Melissa highlights the Alzheimer's Association's multifaceted approach, including care and support, research advancement, and advocacy, while addressing the broader economic and social impacts of dementia. The episode concludes with a call to action for listeners to support Proposition 14 and get involved with the Alzheimer's Association. Key highlights: Melissa Sanchez's Professional Journey Current Role and Proposition 14 Overview Alzheimer's Association Mission and Impact Challenges in Alzheimer's Advocacy Public Health Importance of Dementia How to Support Proposition 14 Resources: Alzheimer's Association website “Vote YES on Proposition 14” campaign Instagram: @alztex X (formerly Twitter): @alztex Facebook: Alzheimer's Association Texas Chapter Other Hill Country Focused Podcasts Hill Country Authors Podcast Hill Country Artists Podcast Texas Hill Country Podcast Network Cover Art Nancy Huffman

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ##FDA Approves New Cancer TreatmentThe FDA has approved a new cancer treatment that has shown promising results in clinical trials. This treatment is expected to provide a new option for patients who have not responded well to traditional therapies. ##Drug Company Announces Major Breakthrough in Alzheimer's ResearchA drug company has announced a major breakthrough in Alzheimer's research, with a new drug that has shown significant improvement in cognitive function in patients with the disease. This breakthrough could potentially change the way Alzheimer's is treated in the future. ##Biotech Startup Raises $50 Million in FundingA biotech startup has raised $50 million in funding to further develop its innovative technology. This funding will allow the company to continue its research and development efforts, with the goal of bringing new treatments to market. ##Pharma Company Expands Manufacturing FacilitiesA pharmaceutical company has announced plans to expand its manufacturing facilities in order to meet growing demand for its products. This expansion will create new jobs and increase production capacity, allowing the company to better serve its customers. ##New Study Shows Promising Results for Diabetes TreatmentA new study has shown promising results for a potential new treatment for diabetes. The treatment, which targets a specific pathway in the body, has shown significant improvements in blood sugar levels and insulin sensitivity in patients with type 2 diabetes. ##Biotech Company Collaborates with Research Institute on Rare Disease TreatmentA biotech company has announced a collaboration with a research institute to develop a new treatment for a rare disease. This partnership brings together expertise from both organizations to work towards finding a cure for this debilitating condition. ##FDA Issues Warning About Counterfeit DrugsThe FDA has issued a warning about counterfeit drugs being sold online. These drugs may not contain the proper ingredients or may be contaminated, posing serious risks to consumers who purchase them. It's important to only buy medications from reputable sources to ensure safety and effectiveness.Support the show

About half a million Texans are living with Alzheimer's disease. Another million Texans serve as unpaid caregivers, managing the daily needs for loved ones. This November, Texas voters will consider Proposition 14, which would direct $3 billion over 10 years to create the Dementia Prevention and Research Institute of Texas. If approved, it would be the largest state-funded Alzheimer's and dementia research program in the nation.

A leading New Zealand research institute is passing the hat to fund the final stages of a clinical trial into a cutting edge treatment for blood cancers. The Malaghan Institute is currently doing clinial trials for CAR-T cell therapy for blood cancer, non-hodgkin lymphoma, with the hope of making it accessible in the public health system. Malaghan Institute Clinical Director, Doctor Robert Weinkove spoke to Lisa Owen.

Clinical research is critical to the development of life saving treatments. And ACCC has long supported equitable access to clinical trials, including efforts to ensure that these trials reflect the diversity of the populations they serve. ACCC has made the Just ASK™ Training Program and Site Self-Assessment available free-of-charge to help research sites address barriers to participation in cancer clinical trials among racial and ethnic populations. In this episode, CANCER BUZZ facilities a candid conversation with Glyniss Redman, who received treatment at Gibbs Cancer Center and Research Institute for multiple myeloma, and 2 members of her cancer treatment team: clinical research coordinator Audrianna Carrington and oncologist hematologist Dr. Tondre Buck, about overcoming barriers, ensuring shared decision-making, and improving the inclusion of historically underrepresented groups in clinical trials.   “If you look at cancers in general, treatments have gotten better over the years in almost every category, and we wouldn't be here if it wasn't for clinical trials.” – Tondre Buck, MD   “We're playing the long game here. Some of the information or this research may not be about me. This is about our future generation…so this is a legacy game for me…This is what I'm doing with my [one] wild and precious life. I want to be here as long as I possibly can, but I also want my offspring: my children, my grandchildren, and my great grandchildren to be here as well and [to] have a better experience as far as health care and cancer.” – Glyniss Redman   “We do have to talk about past unethical experimentation and research in order for us to better prepare how we're going to go forward…[transportation] is one barrier that we are tackling. You know, we don't want to put that stress on the patients who have to choose between gas, their physician visit, their food, or their medicine for the day. So that is a huge barrier, and you really want that population to be represented on the trial, because rural populations tend to have higher cancer rates.” – Audrianna Carrington   Tondre Buck, MD Oncologist Hematologist Gibbs Cancer Center and Research Institute Spartanburg, SC   Audrianna Carrington Clinical Research Coordinator Gibbs Cancer Center and Research Institute Spartanburg, SC   Glyniss Redman Poet and Patient with Multiple Myeloma   Resources:   The Just ASK™ Training Program, Site Self-Assessment, and Training Facilitation Guide   ACORI Call to Action Summit   Clinical Research Terms Glossary   Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator   Gibbs Cancer Center and Research Institute   Cancer Moonshot Biobank   National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data   TalkAboutTrials.com

In this special episode, the creators of SAMR, TPACK, Triple E, SETI, and GenAI-U reflect on how their views of AI in education have evolved since the launch of ChatGPT in November 2022. They share hard lessons learned and insights gleaned, offering a candid look at the ups and downs in their journey through periods of awe, skepticism, and embracing AI's potential. As they prepare to head back to school, they discuss their personal AI use, how their own kids are using AI, and their updated thinking on cheating prevention strategies. The group expands the lens to examine tech companies' AI promises, why Grammarly's new feature is shaking up grading, and how AI is impacting our relationships on many levels. They conclude by sharing how they plan to approach AI differently as they head back to school this term. Follow on X: @CFKurban @hcrompton @lkolb @punyamishra @jonHarper70bd @bamradionetwork Dr. Punya Mishra (punyamishra.com) is the Associate Dean of Scholarship and Innovation at the Mary Lou Fulton Teachers College at Arizona State University. He has an undergraduate degree in Electrical Engineering, two Master's degrees in Visual Communication and Mass Communications, and a Ph.D. in Educational psychology. He co-developed the TPACK framework, described as “the most significant advancement in technology integration in the past 25 years.” Dr. Caroline Fell Kurban is the advisor to the Rector at MEF University. She was the founding Director of the Center of Research and Best Practices for Learning and Teaching (CELT) at MEF University and teaches in the Faculty of Education. She holds a BSc in Geology, an MSc in TESOL, an MA in Technology and Learning Design, and a PhD in Applied Linguistics. Fell Kurban is currently the head of the Global Terminology Project and the creator of the GenAI-U technology integration framework. Dr. Liz Kolb is a clinical professor at the University of Michigan and the author of several books, including Cell Phones in the Classroom and Help Your Child Learn with Cell Phones and Web 2.0. Kolb has been a featured and keynote speaker at conferences throughout the U.S. and Canada. She created the Triple E Framework for effective teaching with digital technologies and blogs at cellphonesinlearning.com. Dr. Puentedura is the Founder and President of Hippasus, a consulting practice focusing on transformative applications of information technologies to education. He has implemented these approaches for over thirty years at various K-20 institutions and health and arts organizations. He is the creator of the SAMR model for selecting, using, and evaluating technology in education and has guided multiple projects worldwide. Dr. Helen Crompton is the Executive Director of the Research Institute for Digital Innovation in Learning at ODUGlobal and Professor of Instructional Technology at Old Dominion University. Dr. Crompton earned her Ph.D. in educational technology and mathematics education from the University of North Carolina at Chapel ill. Dr. Crompton is recognized for her outstanding contributions and is on Stanford's esteemed list of the world's Top 2% of Scientists. She is the creator of the SETI framework. She frequently serves as a consultant for various governments and bilateral and multilateral organizations, such as the United Nations and the World Bank, on driving meaningful change in educational technology.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie is joined by Dr. Justin Turner, community health office for the Cancer Center and Research Institute at UMMC to discuss prostate cancer. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

ASU Professor Dennis Hoffman joins Bruce and Gaydos to discuss today's jobs report.

The People's Liberation Army has displayed all types of its fifth-generation combat planes on active duty for the first time via the grand parade on Wednesday, a move that observers say is intended to show its world-class air prowess.中国人民解放军在周三的盛大阅兵式上，首次展示了现役的所有型号第五代战斗机。观察人士表示，此举旨在彰显中国具备世界一流的空中实力。All of the five models — the J-20, J-20A, J-20S and J-35A of the PLA Air Force as well as the PLA Navy's J-35 — thundered past the Tian'anmen Square in central Beijing as they flew in several arrowhead-shaped groups around the end of a 70-minute parade marking the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression (1931-45) and the World Anti-Fascist War.在这场时长70分钟、纪念中国人民抗日战争（1931-1945）暨世界反法西斯战争胜利80周年的阅兵式临近尾声时，五种型号的战斗机——中国人民解放军空军的歼-20、歼-20A、歼-20S、歼-35A以及海军的歼-35——组成多个箭头形编队，轰鸣着飞过北京市中心的天安门广场。This is the first time in the world that five models of cutting-edge stealth fighter jets have appeared in one parade.这是全球首次有五种型号的尖端隐形战斗机在同一场阅兵式上亮相。It also marked the maiden public performance of the J-20S, the world's first and only model of twin-seat stealth jet; the J-20A, an upgraded single-seat variant of the J-20 baseline configuration; and the J-35, the first radar-evading combat plane in the Navy.此次阅兵也标志着全球首款且目前唯一的双座隐形战斗机歼-20S、歼-20基础型号的升级单座版本歼-20A，以及中国海军首款隐形战斗机歼-35的首次公开亮相。Wang Yanan, chief editor of Aerospace Knowledge magazine, told China Daily that this is the first time in the history of the People's Republic of China that so much new hardware has been sent to a parade.《航空知识》杂志主编王亚男在接受《中国日报》采访时表示，这是中华人民共和国成立以来，首次在阅兵式上展示如此多的新型装备。“What we have seen is an unprecedented unveiling of China's domestically developed weaponry such as those new aircraft. All of these previously unseen weapons have state-of-the-art designs and superior capabilities, and have tremendously enhanced the Chinese armed forces' overall strength,” Wang said.王亚男表示：“我们此次看到的是中国自主研发武器装备——如这些新型战机——前所未有的集中亮相。所有这些此前未公开的武器都具备最先进的设计和卓越性能，极大提升了中国军队的整体实力。”“Specifically speaking, the appearance of the J-20 and J-35 families on a considerable scale means that the Air Force and Navy are in the middle of a systemic transformation that highlights the core role of fifth-generation types, namely these stealth jets,” he said, stating that the PLA is likely to be ahead of other militaries around the globe in terms of establishing a comprehensive fifth-generation air combat system.他指出：“具体而言，歼-20和歼-35系列战机的大规模亮相，表明中国空军和海军正处于以第五代战机（即这些隐形战机）为核心的体系化转型之中。”他还表示，在构建全面的第五代空战体系方面，中国人民解放军可能已走在全球其他军队前列。According to a statement published before the V-Day parade by a temporary command in charge of the event's aircraft squadrons, the new military planes “have been deployed to handle high-intensity warfare” while their appearance was meant to “reflect the PLA's strength to deter adversaries and safeguard China's airspace.”负责此次阅兵式空中梯队的临时指挥部在阅兵前发布声明称，这些新型军机“已列装部队，可执行高强度作战任务”，而它们的亮相旨在“彰显中国人民解放军震慑对手、捍卫中国领空的实力”。J-20S（歼-20S）The J-20S, like other members of the J-20 series, was designed by the Chengdu Aircraft Design and Research Institute, an Aviation Industry Corp of China subsidiary in Sichuan province, and was declassified in November 2024 by appearing in the form of a small-scale mock-up at the 15th China International Aviation and Aerospace Exhibition.与歼-20系列其他型号一样，歼-20S由中国航空工业集团旗下位于四川省的成都飞机设计研究所设计，并于2024年11月在第十五届中国国际航空航天博览会上以小型模型形式首次解密。According to designers at AVIC, the J-20S is a heavy-duty radar-evading fighter jet with long-range operation and multifunction capabilities.中国航空工业集团的设计师表示，歼-20S是一款具备远程作战能力和多功能属性的重型隐形战斗机。The twin-seat plane is characterized by its supreme ability to seize superiority in air combat, carry out precision strikes against land and sea targets, and perform battlefield situational awareness, electronic jamming as well as tactical command and control operations.这款双座战机的核心优势在于：具备极强的夺取制空权能力、可对陆基和海基目标实施精确打击，同时能执行战场态势感知、电子干扰及战术指挥控制任务。In addition to conventional tasks, the J-20S can team up with unmanned planes in air combat, designers said.设计师还指出，除常规任务外，歼-20S还可在空战中与无人机协同作战。Fu Qianshao, an aircraft researcher who had served with the Air Force for decades, said the jet is likely to be tasked with conducting electronic warfare operations or guiding unmanned aircraft to hit enemy targets.曾在空军服役数十年的航空研究员傅前哨表示，歼-20S可能承担电子战任务，或引导无人机打击敌方目标。“The additional operator in the backseat is responsible for controlling electronic warfare instruments or coordinating strike operations by his or her plane and attack drones. His or her work can enable the J-20S to better use precision-guided munitions and connect with the airborne early-warning and control systems,” he said. “It is better to have an operator to focus on these extended functions because only one pilot would be too busy to take care of all of those tasks in real air combat.”他解释道：“后座的额外操作员负责操控电子战设备，或协调本机与攻击型无人机的打击行动。这一设置能让歼-20S更高效地使用精确制导武器，并与空中预警指挥系统联动。在实际空战中，仅靠一名飞行员难以兼顾所有任务，专门安排一名操作员负责这些扩展功能更为合理。”An extra seat will bring more benefits than these, the veteran researcher added.这位资深研究员补充称，双座设计的优势不止于此。"The twin-seat variant can have a backup flight-control system installed for the backseat operator to use in case the main system malfunctions or is damaged in action, or the front-seat pilot becomes incapacitated.“双座型号可搭载备用飞行控制系统，若主控制系统在作战中出现故障或受损，或前座飞行员失去行动能力，后座操作员可启动备用系统操控战机。“It can also be used to train new aviators to make them familiar with the cutting-edge fighter jet as quickly as possible,” Fu stated.傅前哨表示：“此外，歼-20S还可用于培训新飞行员，帮助他们尽快熟悉这款尖端战机。”J-20A（歼-20A）Another J-20 variant — the J-20A — has several external differences from the baseline model: an enlarged spine, reshaped nosecone, and modified engine intakes optimized for new, mightier engines developed by Chinese engineers on their own.歼-20的另一改进型号歼-20A与基础型号在外观上有多处不同：机身脊背加长、机头重新设计，且发动机进气道经过优化，以适配中国工程师自主研发的新型大功率发动机。Its engines are widely believed to have thrust vector control technology that provides significant benefits in flight maneuverability.外界普遍认为，歼-20A的发动机配备了推力矢量控制技术，这一技术能显著提升战机的飞行机动性。The technology enables a pilot to adjust the engine exhaust nozzles to redirect thrust, allowing the plane to carry out previously unimaginable maneuvers at very high angles of attack, meaning its nose is pointed at an angle greatly exceeding the jet's current vector.通过这项技术，飞行员可调整发动机尾喷口方向以改变推力方向，使战机能在超大迎角（机头指向与飞行轨迹夹角远大于常规范围）下完成以往难以实现的机动动作。This capability is expected to be a great advantage for fighter aviators when evading a missile or seeking an advantageous position in within-visual-range air combat.这种能力使战机在规避导弹或近距离空战中抢占优势位置时，能为飞行员提供显著优势。In addition to stunning tactical maneuvers, the new powerplants may also bring about higher fuel efficiency and longer flight range.除实现出色的战术机动外，新型发动机还可能提升燃油效率，延长战机航程。Wang Yanan, chief editor of Aerospace Knowledge magazine, said the J-20A's optimized aerodynamic configuration, especially the slightly raised spine, has created a direct benefit: a bigger inner space that can be used for extra sensors or fuel tanks.《航空知识》杂志主编王亚男表示，歼-20A优化的气动布局——尤其是略微抬高的机身脊背——带来了一项直接优势：增加了内部空间，可用于加装额外传感器或油箱。"Raising the spine was not feasible for previous types of fighter jets because their pilots depend more or less on their bare eyes to spot suspicious objects so their cockpit canopy should have a 360-degree visual field, particularly in the backward direction.“以往的战斗机无法采用抬高脊背的设计，因为那时的飞行员多少需要依靠肉眼观察可疑目标，因此座舱盖需具备360度视野，尤其是向后的视野必须开阔。“Now, thanks to avionics enhancements and sensor improvements, a J-20A pilot no longer needs to turn his or her head to observe situations behind as several passive electro-optical sensors mounted around the fuselage can give the aviator an omnidirectional view,” the editor explained, adding that the redesigned spine also helps to reduce aerodynamic drag.“如今，得益于航空电子设备和传感器的升级，歼-20A的飞行员无需转头观察后方情况——机身周围安装的多个被动光电传感器可为飞行员提供全方位视野。”王亚男还补充称，重新设计的脊背也有助于降低气动阻力。J-35A（歼-35A）Another recent addition to the Air Force's stealth arsenal, the J-35A, also partook in the parade's air performance.（歼-35A是中国空军隐形装备库中近期新增的型号，此次也参与了阅兵式的空中梯队展示。）Designed by AVIC's Shenyang Aircraft Design and Research Institute in Liaoning province, the J-35A is a single-seat, twin-engine stealth multirole fighter with a conventional aerodynamic configuration.歼-35A由中国航空工业集团旗下位于辽宁省的沈阳飞机设计研究所设计，是一款采用常规气动布局的单座双发隐形多用途战斗机。According to its designers, the jet's primary task is to seize and maintain air superiority, with a secondary mission of carrying out airstrikes against land and sea targets.设计师介绍，这款战机的首要任务是夺取并保持制空权，次要任务是对陆基和海基目标实施空中打击。Specifically, the jet will be used to engage with hostile aircraft including fighters and bombers, shoot down enemy cruise missiles, and eliminate adversaries' land- and ship-based air defense hardware.具体而言，歼-35A可用于对抗包括战斗机、轰炸机在内的敌方航空器，击落敌方巡航导弹，并摧毁敌方陆基和舰载防空装备。Wang Mingzhi, a senior researcher with the Air Force, said the J-20 series and J-35A will complement each other in air combat in the future.中国空军高级研究员王明志表示，未来在空战中，歼-20系列与歼-35A将形成互补。“The heavy-duty J-20 models will be used to fight for air dominance while the midsize J35A will be suitable for various kinds of operations ranging from engaging with hostile fighters to precision assaults against land and sea targets,” he said.他指出：“重型的歼-20系列将用于争夺制空权，而中型的歼-35A则适用于多种任务，既可以与敌方战斗机对抗，也能对陆、海目标实施精确打击。”The J-35A made its first public flight performance at the 15th China International Aviation and Aerospace Exhibition, shortly after it was declassified by the Air Force.歼-35A在中国空军解密后不久，便于第十五届中国国际航空航天博览会上完成了首次公开飞行展示。Following the recent delivery of the first batch of J-35As, China has become the second nation after the United States to have two families of stealth fighter jets in active service.随着首批歼-35A近期列装部队，中国成为继美国之后，全球第二个拥有两个系列现役隐形战斗机的国家。Y-20B（运-20B）Besides these new fighter jets, the Air Force also sent a re-engined version of its Y-20 strategic transport aircraft to fly in the parade.除这些新型战斗机外，中国空军还派出了换装新型发动机的运-20战略运输机参与阅兵式空中梯队。Compared with the baseline model in the Y-20 family, the Y-20B cargo jet's most distinctive trait is its new propulsion system, which appears to consist of four domestically designed high-bypass turbofan engines.与运-20基础型号相比，运-20B运输机最显著的特征是其新型推进系统——似乎配备了四台中国自主设计的大涵道比涡扇发动机。The Y-20's baseline configuration took its maiden flight in January 2013, and began to be delivered to the Air Force in July 2016. It uses four Russian engines as powerplants.运-20基础型号于2013年1月完成首飞，2016年7月开始交付中国空军，其动力系统采用四台俄罗斯发动机。Wang Yanan, chief editor of Aerospace Knowledge magazine, said that the new domestically built engine has stronger thrust and lower fuel consumption, and that means the Y-20B is now able to fly farther and carry more cargo. Consequently, the new transport aircraft allows the PLA to deploy and sustain its forces over much greater distances, as befitting a true global power, he added.《航空知识》杂志主编王亚男表示，这款国产新型发动机推力更大、油耗更低，这使得运-20B的航程更远、载重量更大。他补充称，这款新型运输机使中国人民解放军能够在更远距离内部署和保障部队，符合一个真正全球性大国的能力需求。On the ground, multiple new types of combat drones were carried by trucks traveling in the parade, pointing to the possibility that the Air Force may place more duties on the pilotless jets.在地面装备方队中，多款新型作战无人机由卡车搭载亮相，这表明中国空军可能会赋予无人机更多任务职责。Wu Peixin, an aviation industry observer, said that it has been a shared trend for air powers to integrate their stealth fighters with uncrewed platforms' capabilities.航空行业观察家吴培新表示，将隐形战斗机与无人平台能力相融合，已成为全球空中力量发展的共同趋势。“A stealth jet is very expensive and sophisticated, while a drone is much cheaper, and is expendable. In air combat, pilots of stealth jets can operate and guide a group of strike drones to launch missiles toward targets and even hit the targets by themselves, without risking the safety of the pilots and their jets. Those unmanned planes will also be able to detect signals of enemy assets and then autonomously chart out a route to penetrate defense and take out the targets,” he said, adding that this new pattern will definitely revolutionize air combat in the future.他解释道：“隐形战斗机成本高昂、技术复杂，而无人机成本更低且可作为消耗性装备使用。在空战中，隐形战斗机飞行员可操控并引导一组攻击型无人机向目标发射导弹，甚至由无人机自主打击目标，无需让飞行员和战机面临风险。这些无人机还能探测敌方装备信号，自主规划突防路线并摧毁目标。”他补充称，这种新模式未来必将彻底改变空战形态。

Ileana Najarro, reporter for Education Week covering race and opportunity in U.S. schools, and Kate Menken, professor of linguistics and a research fellow at the Research Institute for the Study of Language in an Urban Society at Queens College of the City University of New York (CUNY) and co-editor in chief of the journal Language Policy, discuss the news that the Trump administration has rescinded a 2015 directive standards for English Language Learners in U.S. schools.

In business and in life, the most dangerous risk you can take is avoiding risk altogether. Whether it's leading a team, making strategic investments, or navigating unpredictable markets, risk is always present, yet most leaders misunderstand how to harness it. In this episode, Jim McCormick, best-selling author (The First Time Manager, The Power of Risk) and founder of the Research Institute of Risk Intelligence, shares lessons from 5,590 skydives, high-stakes political decision-making, and years of advising executives on building “risk intelligent” organizations. He breaks down why people are naturally risk-averse, the two-part “Risk Equation” leaders must master, and how to balance instigators and mitigators for optimal decision-making. You'll learn how to assess opportunities using ideal, most likely, and worst-case scenarios, implement “Possibility of Success Enhancement Measures” (POSSUMS) to improve outcomes, and set guardrails that encourage innovation without micromanagement. Jim also explores how to measure personal and team Risk Quotients, create cultures that reward constructive risk-taking—even when initiatives fail—and avoid the trap of over-relying on AI for critical decisions.   ________________ Start your day with the world's top leaders by joining thousands of others at Great Leadership on Substack. Just enter your email: ⁠⁠https://greatleadership.substack.com/  

For most of us, workplace engagement isn't a solo sport—it's a team one. The ADP (yes, the payroll people) Research Institute's study across 19 countries found that most of us, regardless of company size, are immersed in team life. In companies of 150 or more employees, 82% of employees work on teams, and nearly 3/4ths juggle more than one team. Even if your employer has fewer than 20 people, 2/3rds of us are teaming up on one, two or even three teams. This matters: team membership doubles our odds of scoring high on Gallup's engagement metrics, with this research concluding that the sweet spot belonging is being on five distinct teams. It is not just the number of teams, but whether we trust the team leader that can make us 12 times more likely to be fully engaged. Let's go back to the holy grail of Google's Project Aristotle, which took team-obsession to a new level.  Google spent twp years studying 180 teams to crack the high-performing team code. They discovered that talent and resources aren't the magic ingredients—they're just the gravy. The meat and potatoes or tofu and rice for the team? Psychological safety—the freedom to speak up, take risks, and make mistakes without fear of public humiliation. It turns out, when people feel safe to contribute, they get bold, creative, and collaborative.  Leaders create psychological safety with dependability, structure and clarity, meaning, and impact.  McKinsey's research builds on this, showing that effective teams come in different “archetypes.” A cycling team is like a NASCAR pit crew—specialized, coordinated, but with independent metrics. Agile software teams are more like relay squads—high interdependence and shared outcomes, where dropped balls ripple through the race. Surgical teams? Think rowing crew—total synchronicity, clearly defined roles, and an unshakable sense of belonging.   To truly hum, teams need to tend to their “health drivers,” grouped into four areas. Configuration means having the right roles and perspectives. Alignment is clarity on purpose and shared commitment. Execution covers collaboration, communication, decision making, and feedback. Renewal—the often-overlooked one—ensures long-term sustainability through belonging, psychological safety, recognition, and trust. Not every team needs to nail all of the team health drivers - of the 17 identified health drivers even top performing teams are only “very good” at about 11, which is like a C-! Four health drivers stand out as the performance heavyweights: trust, communication, innovative thinking, and decision making.  Much of this is what we know - what is surprising is that just getting some of the elements that create healthy and effective teams right is a game-changer in the workplace.

Dr. John Greene, Professor of Medicine and Chief of Infectious Diseases at Moffitt Cancer and Research Institute, conducts this photo review of various human endemic fungal infections. Covered topics include mycetoma, chromoblastomycosis, phaeohyphomycosis, Sporotrichosis, cryptococcosis, histoplasmosis, blastomycosis, coccidioidomycosis, and paracoccidioidomycosis. The presentation is suitable for infectious diseases board examination testing.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Ad astra Travelers! Welcome to another episode of Tales of Teyvat: A Genshin Lore Podcast. This week we're heading to the wacky water cubes in the sky to discuss the Fontaine Research Institute of Kinetic Energy. After a brief recap of the major groups that existed across the Nation of Justice 500 years prior to the game's start, our hosts discuss the founding of the Institute from our favorite orphan of the Narzissenkreuz Institute - Alain Guillotin. Once we review his textbook of accomplishments, we discuss the original purpose of the Institute: fighting the Fontaine prophecy. But what happens when the flood has passed? What is the Institute up to in a modern Teyvat? Are they looking to become Celestia? To Invent the best flavor of Fonta ever made? Or are they looking to simply blow things up? Grab your helmet and a glass of ice for this week's episode! Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠talesofteyvat.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to find a comprehensive lore sheet that provides visual aids and links to videos and important Genshin Impact Resources. Make sure to give us a follow on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to stay updated on all things Tales of Teyvat and let us know your thoughts on today's episode. Questions? Thoughts? Theories you have to share? Feel free to email us at talesofteyvatpod@gmail.com and let us know, we would love to hear from you!Tales of Teyvat has partnered with the Shade Chamber Podcast to create a Genshin Community on Discord for our listeners! We are so excited to chat Genshin Lore, Honkai Star Rail, and so much more with you! You can join our server at https://bit.ly/shadesofteyvat.

August 12, 2025: Dr. Zafar Chaudry, SVP, CDIO, and AI Officer, speaks with Dr. Vittorio Gallo, Chief Scientific Officer at Seattle Children's Research Institute, about the transformation happening in pediatric research. As healthcare shifts from traditional lab work to data-driven science, how are research institutions keeping pace with the explosion of information they're generating? Vittorio discusses breakthrough therapies currently in development, including the first clinical trial for cell immunotherapy in pediatric lupus and innovative approaches to treating neonatal brain injuries. But with massive datasets requiring decades of storage and AI models now identifying developmental disorders through behavioral analysis, what does this mean for the relationship between technology teams and researchers?Key Points:03:40 Innovative Pediatric Therapies10:53 Future Directions in Data Science16:02 Future Projects and AI Applications22:44 Mentorship and Advice for Young ScientistsX: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Sixty years ago today, President Lyndon B. Johnson signed the 1965 Voting Rights Act, saying “The denial of the right to vote, is still a deadly wrong and the time for injustice has gone.” Today, we look back on the landmark legislation and the challenges voting rights see today. Joining Rose Scott for today’s special call-in edition of “Closer Look,” we’re joined by Andra Gillespie, Associate Professor of Political Science and Director of the James Weldon Johnson Institute at Emory University. Also, Dr. Clarissa Myrick-Harris White, a Professor of Africana Studies at Morehouse College and co-founder of the college’s Black Men’s Research Institute and co-principal investigator for the Morehouse Movement, Memory, and Justice.See omnystudio.com/listener for privacy information.

Professor Dennis Hoffman joins Bruce and Gaydos to discuss the state of the U.S. economy.

Dr. Robert Castro, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents this review on infections associated with vector-borne and zoonotic exposures. Dr. Castro begins by discussing vector -borne infections, dividing them into mosquito-borne and tick-borne diseases. Syndromes discussed include Dengue, Chikyunguna, West Nile Virus, and Japanese Encephalitis. Next, Zoonotic infections such as Rabies Virus, Hantavirus, Orf virus, and B virus are covered. Dr. Castro closes by discussing vector control strategies.

Got a story idea for Bloodworks 101? Send us a text message What do you know about AI? As you're probably aware, there's way more to AI than what you get from ChatGPT. In fact, as the team at Bloodworks Research can tell you, the potential for machine learning to one day save lives is very real. Bloodworks 101 producer John Yeager spoke with Dr. Jose Lopez, Bloodworks Chief Scientific Officer, along with Gabe Richman, Founder & CEO of Omic, a drug discovery and AI company, on how we're working together to advance treatments for diseases that impact many of us.

Studies have shown that infants, children, and adolescents are at a greater risk of traumatic brain injuries than any other age group. Professor Vicki Anderson from Melbourne's Murdoch Children's Research Institute spoke to Ingrid Hipkiss.

Due to the US holiday, 4th of July, I am re-publishing one of our greatest hits and most popular episodes. The “Best of 2024” episode features sixteen don't miss moments from HR executives and thought leaders who…So, who can you expect to learn from on this episode? Rhonda Morris, CHRO, ChevronJeffrey Pfeffer, Professor Stanford University and Author of 16 books including the “7 Rules of PowerKerrie Peraino, Chief People Officer at VerilyKevin Wilde, Executive Leadership and Talent Development Expert & AuthorKelly Monahan, Managing Director, Research Institute at UpworkDave Ulrich, Bob Eichinger, and Allan ChurchLybra Clemons, a C-Suite executive with experience leading talent, culture, and DEI Shaun Mayo, Chief People Officer, Arizona Cardinals Football ClubAmy Kates, Organization Design Expert, Consultant, Educator, and Author of Five BooksKevin Cox, Founder and President of LKC Advisory & Anthony Nyberg, Director, Center for Executive Succession at University of South CarolinaJordana Kammerud, SVP & CHRO, CorningLucien Alziari, EVP and CHRO of Prudential Financial, IncGinger King, CHRO, Kohler Co.Tim Richmond, EVP & Chief Human Resources Officer, AbbVieStephanie Lilak, EVP & Chief People Officer, Mondelez InternationalPrasad Setty, Lecturer, Stanford GSB, Advisor, Former VP at Google, People Ops and WorkspaceEpisode Sponsor: Next-Gen HR Accelerator - Learn more about this best-in-class leadership development program for next-gen HR leadersHR Leader's Blueprint - 18 pages of real-world advice from 100+ HR thought leaders. Simple, actionable, and proven strategies to advance your career.Succession Planning Playbook: In this focused 1-page resource, I cut through the noise to give you the vital elements that define what “great” succession planning looks like.

Rising inequality is a concern for governments and everyday people – but it might be useful to put the current situation into historical perspective. Daniel Waldenstrom is professor of economics and program manager for the research program Taxes and Society at the Research Institute of Industrial Economics in Stockholm. He joins host Krys Boyd to discuss why understanding the metrics of measuring inequality is critical to understanding that not all people — or even countries — are being as hard hit as we might believe. Plus, we'll talk about what might actually work to address poverty. His article in Foreign Affairs is “The Inequality Myth,” and his book published last year is “Richer and More Equal: A New History of Wealth in the West.” Learn about your ad choices: dovetail.prx.org/ad-choices

JUST HOW UNEQUAL IS OUR WEALTH? If you listen to Bernie Sanders rich people are literally stealing the change from poor people's pockets, but of course that is false. But the Gospel of Wealth Inequality is a powerful elixir doled out to gin up envy and greed in the people and it's effective. But is it true? At 1 I'm talking with Daniel Waldenstrom, Professor of Economics, Research Institute of Industrial Economics, Stockholm, Sweden Previously professor at Paris School of Economics, Uppsala University, UCLA about his work on it, and it tells a much different story. Read this for more, but we will dig in today. Find his book on the subject, Richer and More Equal: A New History of Wealth in the West by clicking here.

This week, Kim and I have a vulnerable discussion about my risk of Alzheimer's Disease. Three of my four grandparents, my late father, and my mother have all struggled with Alzheimer's and dementia. As I have grown older, the fear of developing it has always been in the back of my mind. But I have something all of my family didn't - new information on how to TRY to prevent it.We are honored to have Dr. Richard Isaacson join us and share his research as one of the leading voices in Alzheimer's disease prevention. Dr. Richard Isaacson is Director of Research at The Institute for Neurodegenerative Diseases (IND) and Director of the Precision Prevention Program at Atria Health and Research Institute. His research explores how lifestyle interventions can help reduce the risk of Alzheimer's. We discuss everything from how Ozempic may help to what supplements not to take. I also try to keep things light with the "Top 5 Funniest Things About Alzheimer's" at the end of the show (and Kim gives a #NotSponsored endorsement and update on her Road To 50!) Have you been personally impacted by Alzheimer's? We would love to hear what you think! Leave us a voicemail at 323-364-3929 or write the show at podcast@theholdernessfamily.com. You can also watch our podcast on YouTube.Check your Omega-3 levels at omegaquant.comAddress specific risk factors at retainyourbrain.comFind free resources and donate to Dr. Isaacson's research at IND.orgVisit Our ShopJoin Our NewsletterFind us on SubstackFollow us on InstagramFollow us on TikTok Follow us on FacebookLaugh Lines with Kim & Penn Holderness is an evolution of The Holderness Family Podcast, which began in 2018. Kim and Penn Holderness are award-winning online content creators known for their original music, song parodies, comedy sketches, and weekly podcasts. Their videos have resulted in over two billion views and over nine million followers since 2013. Penn and Kim are also authors of the New York Times Bestselling Book, ADHD Is Awesome: A Guide To (Mostly) Thriving With ADHD and winners on The Amazing Race (Season 33) on CBS. Laugh Lines is hosted and executive produced by Kim Holderness and Penn Holderness, with original music by Penn Holderness. Laugh Lines is also written and produced by Ann Marie Taepke, and edited and produced by Sam Allen. It is audio engineered by Max Trujillo and hosted by Acast. Thanks for listening! Hosted on Acast. See acast.com/privacy for more information.